BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16382404)

  • 1. [How should patients with completely resected gastrointestinal stromal tumours (GIST) be followed up?].
    Stelzner S; Antoni C; Haroske G; Jacobasch L; Erk JU; Ludwig K
    Zentralbl Chir; 2005 Dec; 130(6):554-61. PubMed ID: 16382404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
    Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
    Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gastrointestinal stromal tumour: our experience].
    Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
    Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
    Nilsson B; Sjölund K; Kindblom LG; Meis-Kindblom JM; Bümming P; Nilsson O; Andersson J; Ahlman H
    Br J Cancer; 2007 Jun; 96(11):1656-8. PubMed ID: 17533389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical resection of esophageal gastrointestinal stromal tumors.
    Lee HJ; Park SI; Kim DK; Kim YH
    Ann Thorac Surg; 2009 May; 87(5):1569-71. PubMed ID: 19379907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J; Wang Y; Hou M; Li HY; Zhang J
    Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
    Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
    Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness.
    Kosmadakis N; Visvardis EE; Kartsaklis P; Tsimara M; Chatziantoniou A; Panopoulos I; Erato P; Capsambelis P
    Surg Oncol; 2005 Aug; 14(2):75-84. PubMed ID: 15993051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours.
    Bümming P; Ahlman H; Andersson J; Meis-Kindblom JM; Kindblom LG; Nilsson B
    Br J Surg; 2006 Jul; 93(7):836-43. PubMed ID: 16705644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
    J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
    Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M
    Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
    Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
    Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery for gastrointestinal stromal tumour in the post-imatinib era.
    Neuhaus SJ; Clark MA; Hayes AJ; Thomas JM; Judson I
    ANZ J Surg; 2005 Mar; 75(3):165-72. PubMed ID: 15777399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
    Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
    Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.